Skip to main content
All lobbying filings

VIZIENT, INC.

Lobbying for VIZIENT INC

 Filing 3rd Quarter - Report
3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $320,000.00 expenses · posted Oct 20, 2025

Official filing document

 Bills named in this filing 14
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • HR 5454
    Medicare Advantage Prompt Pay Act
  • S 1784
    MAPS Act
  • HR 4191
    MAPS Act
  • S 1954
    Biosimilar Red Tape Elimination Act
  • S 2439
    Resident Physician Shortage Reduction Act of 2025
  • HR 3890
    Resident Physician Shortage Reduction Act of 2025
  • HR 4731
    Resident Physician Shortage Reduction Act of 2025
  • S 2279
    Protect Medicaid and Rural Hospitals Act
  • S 2556
    Protecting Health Care and Lowering Costs Act
  • S 1600
    Save Healthcare Workers Act
  • HR 3178
    Save Healthcare Workers Act
  • S 998
    Medical Supply Chain Resiliency Act
  • HR 2213
    Medical Supply Chain Resiliency Act
 Lobbying activity 4
Medicare/Medicaid

Acute Hospital Care at Home - Recommended Congress make certain flexibilities related to the Acute Hospital Care at Home Program permanent or, pass an extension before flexibilities expire. Issues related to hospital and provider payment - Supported increasing hospital reimbursement to ensure continued access to care for vulnerable populations, highlighted the criticality of Medicaid to sustaining vital healthcare services. Medicaid Disproportionate Share Hospital (DSH) Program - Urged Congress to avert the cuts to Medicaid DSH payments set to take place, encouraged passage of legislation to preserve DSH payments on a longer-term basis Medicaid Program; Preserving Medicaid Funding for Vulnerable Populations- Closing a Health Care-Related Tax Loophole Proposed Rule (CMS- 2448-P) - Responded to various issues and proposals provided in the Proposed Rule and encouraged the agency to identify alternative approaches that would be less disruptive to state Medicaid programs. Medicare and Medicaid Programs; CY 2026 Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Overall Hospital Quality Star Ratings; and Hospital Price Transparency (CMS-1834-P) proposed rule - Responded to various issues and proposals provided in the Proposed Rule and offered our responses to the agencys various requests for information. Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program (CMS-1832-P) proposed rule - Responded to various issues and proposals provided in the Proposed Rule and offered our responses to the agencys various requests for information. Medicare Program; Implementation of Prior Authorization for Select Services under the WISeR Model (CMS-5056-N) - Offered recommendations to strengthen transparency, reduce administrative burden and ensure provider perspectives inform implementation and oversight Monitored development and passage of the One Big Beautiful Bill Act (H.R.1) Physician Payment - Urged Congress to consider long-term legislative solutions to refine the current Medicare physician payment system Prior Authorization - Provided feedback to improve prior authorization (PA) processes for various plans and payers, including MA organizations and Medicaid managed care plans. Monitored development of the Medicare Advantage Prompt Pay Act (H.R.5454) Rural Emergency Hospital (REH) Designation - Urged corrective action to allow REHs to bill both the Medicare and Medicaid programs. Advocated for increased eligibility among REHs to allow for future Medicaid DSH payments to certain hospital facilities. Site-Neutral Payment Policies - Opposed adoption of site-neutral payment policies for drug administration and increased fines related to price transparency requirements for hospitals. Urged Congress to redirect its focus from site-neutral payment policies to reducing administrative burdens and increasing, rather than reducing, payments for care delivery in rural areas.

Health Issues

340B Drug Pricing Program - Continued to urge action to ensure covered entities have access to 340B discounted prices through contract pharmacies. Highlighted critical importance of the 340B program for hospitals. 340B Program Notice: Application Process for the 340B Rebate Model Pilot Program (HHS Docket No. HRSA-2025-14619) - Provide feedback to the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) notice and request for comments (RFC) regarding the application process for the 340B Rebate Model Pilot Program Drug shortages - Supported elements to increase transparency in prescription drug supply chain and increase reimbursement for generic prescription drugs; issues related to compounding; issues related to buffer inventory. Encouraged improved stakeholder communication and increased notification by manufacturers for a surges in demand Endorsed passage of the Mapping Americas Pharmaceutical Supply (MAPS) Act (S.1784/H.R.4191) Endorsed passage of the Biosimilar Red Tape Elimination Act (S.1954) Endorsed passage of the Resident Physician Shortage Reduction Act of 2025 (S.2439/H.R.3890/H.R.4731) Endorsed passage of the Protect Medicaid and Rural Hospitals Act (S.2279) Endorsed passage of the Protecting Health Care and Lowering Costs Act (S.2556) Hospital Group Purchasing - Advocated to highlight the value that hospital group purchasing organizations provide to hospitals and suppliers. Provided education on how GPOs work in the healthcare supply chain and the role they play in delivering value to healthcare providers, as well as key differences between traditional GPOs and PBMs. Hospital Price Transparency - Responded to CMS Hospital Price Transparency Accuracy and Completeness Request for Information (RFI), urge the agency to alleviate excessive administrative burden on providers. Monitored development and passage of the One Big Beautiful Bill Act (H.R.1) Mental and Behavioral Health - Highlighted the need for legislation to address significant challenges to mental and behavioral health treatment, including increased demand for services, limited access to treatment, and clinician shortages. Non-medical drivers of health outcomes - Encouraged Congress and agencies to ensure tools like the Vizient Vulnerability Index are being utilized to understand data about disparities in health. Highlighted opportunities for the increased use of secondary health data in a clinical setting. Payer-mandated White Bagging - Urged support for policy updates related to payer-mandated white bagging for medications Rural healthcare - Advocated for policies and initiatives that address the challenges of rural communities by promoting access to care and strengthening healthcare infrastructure Telehealth - Continued to advocate for the adoption of permanent telehealth policies to extend flexibilities beyond the current expiration date. Ultra-Processed Foods; RFI (Docket No. FDA-2025-N-1793) - Responded to FDA and USDAs request for information encouraging efforts to consider a uniform, science-based definition of UPFs through coordinated federal efforts Workforce - Advocated for strengthening the health workforce through policies that support education, training, recruitment, and retention efforts. Continued monitoring and encouraged passage of the Save Healthcare Workers Act (S.1600/H.R.3178). Hosted congressional briefing educating Senate and House staff on the education and training needs to address healthcare worker shortages, burnout and workplace violence.

Taxation/Internal Revenue Code

Monitored development and passage of the One Big Beautiful Bill Act (H.R.1) Not-for-Profit Hospital Tax-exemption - Provided education and information on hospital tax exemption and what is required to justify and maintain tax-exempt status.

Tariff (miscellaneous tariff bills)

Imports of personal protective equipment (PPE), medical consumables, and medical equipment, including Devices: Monitored and provided feedback on U.S. Department of Commerces Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Personal Protective Equipment, Medical Consumables, and Medical Equipment, Including Devices (Docket No: 250924-0160; XRIN 0694-XC134) Monitored development of the Medical Supply Chain Resiliency Act (S.998/HR.2213) United States and European Union Cooperation Agreement on Reciprocal, Fair and Balanced Trade - Monitored Implementation and passage of agreement, with focus on tariff barriers.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem